Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
WZ4003 Lowers Tau pSer356 in Brain Models
2026-08-24
Taylor et al. linked tau phosphorylation at Ser356 to Alzheimer’s disease pathology and showed that the NUAK1/2 inhibitor WZ4003 lowers this modification in live human brain slice cultures. The study also reveals important model-dependent effects in mouse organotypic slices, providing a framework for interpreting NUAK inhibition in translational neurodegeneration research.
-
JXY, TLR4, and M1 Macrophages in Colitis-Associated CRC
2026-08-23
Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-associated state through TLR4-linked signaling. The study combines an orthotopic cancer model with macrophage assays and pharmacological pathway interrogation, providing a useful framework for connecting tumor progression with immune-microenvironment remodeling.
-
Thymoquinone Workflows for Cardiotoxicity Research
2026-08-22
Build reproducible doxorubicin cardiotoxicity assays around Thymoquinone, from solvent handling through ferroptosis, oxidative-stress, and cardiac-function readouts. The workflow separates study-matched mouse dosing from practical cell-culture optimization while highlighting controls that distinguish antioxidant protection from nonspecific cytotoxicity.
-
IGFBP2–THBS1 Mechanism in GH-Treated ISS
2026-08-22
This study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its combination of patient plasma data, bioinformatic interaction prediction, and gain- and loss-of-function experiments provides a mechanistic framework for studying variable responses to GH therapy.
-
β-Elemene: From Adipogenesis to Assay Insight
2026-08-21
β-Elemene is more than an adipogenesis inhibitor: it is a context-dependent tool for separating phenotype, metabolism, and pathway response. This article interprets recent 3T3-L1 evidence and translates it into reproducible assay and cross-domain research decisions.
-
Everolimus (RAD001): Readouts That Matter
2026-08-20
Everolimus (RAD001) is an orally bioavailable mTOR inhibitor whose pathway activity should be separated from cytostasis and cell death. This assay-centered guide shows how to design more informative cancer experiments by integrating mechanistic, proliferation, and apoptosis readouts.
-
IRG1-Itaconate Control of TBK1 and Type I IFN
2026-08-20
A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains excessive TBK1-driven type I interferon production. The work connects itaconic acid–dependent alkylation of TBK1 at Cys605 with impaired dimerization and introduces ITA-5 and ITA-9 as candidate inhibitors for IFN-I-mediated hyperinflammation.
-
Rapamycin (Sirolimus) for mTOR Assays
2026-08-19
Rapamycin (Sirolimus) provides a precise chemical perturbation strategy for mTOR-driven studies spanning cancer, autophagy, immunology, and mitochondrial disease models. This practical guide connects dose–time design with EBV-associated gastric cancer biology, pathway validation, and troubleshooting for reproducible cell assays.
-
PP 2 (AG 1879): From Src Biology to Translation
2026-08-19
PP 2 (AG 1879) is more than a Src-family kinase reagent: it is a context-dependent probe for separating target engagement from pathway causality. This article connects its cancer and immune applications with vascular evidence showing that Src inhibition can reduce contraction without mediating NADPH oxidase-derived ROS effects, providing a practical framework for translational study design.
-
TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows
2026-08-18
TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, osteoclastogenesis, and Nrf2 biology. This workflow-focused guide shows how to formulate it, confirm EET/DHET target engagement, and troubleshoot cell, lipidomics, and cross-species experiments.
-
BPN-19186: Osteoclastogenesis Assay Workflows
2026-08-18
BPN-19186 provides a practical small-molecule entry point for testing enzyme inhibition studies, redox signaling, and osteoclast differentiation without relying exclusively on genetic perturbation. This workflow emphasizes exposure control, orthogonal Nrf2-related readouts, metabolite analysis, and troubleshooting for reproducible biochemical research.
-
KU-60019: ATM Kinase Inhibitor Workflow
2026-08-17
KU-60019 supports controlled studies of ATM-dependent DNA damage signaling, glioma radiosensitization, and migration or invasion phenotypes. This workflow connects selective pathway inhibition with practical assay controls, formulation guidance, and mechanistic experiments inspired by lncRNA-regulated ATM biology.
-
Losartan for AT1R and Diabetic Kidney Research
2026-08-17
Losartan combines selective AT1 receptor antagonism with a practical workflow for connecting angiotensin II signaling to vascular and podocyte phenotypes. This guide translates recent diabetic nephropathy findings into assay-ready dosing, internalization measurements, matrix readouts, and troubleshooting strategies.
-
Phosbind Acrylamide for Phosphorylation Analysis
2026-08-16
Phosbind Acrylamide enables antibody-independent separation of phosphorylated and non-phosphorylated proteins in a familiar SDS-PAGE workflow. This article shows how to apply it to heat-stress transcription studies, kinase assays, control design, and troubleshooting when phosphorylation-dependent mobility shifts are subtle.
-
Recombinant Human FGF-19 Assay Guide
2026-08-15
A scenario-based guide to using Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, in proliferation, viability, binding, and metabolic regulation research. It connects product specifications with practical controls, reconstitution, storage, and interpretation strategies for reproducible cell-based assays.